Gilead Sciences, Inc. (GILD)

66.16 -0.77 (-1.15%) 收市：04:00PM EDT

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 18,000

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Daniel P. O'Day	Chairman & CEO	6.99M	無	1964
Mr. Andrew D. Dickinson	Chief Financial Officer	2.66M	無	1970
Ms. Deborah H. Telman	Executive VP of Corporate Affairs, General Counsel & Corporate Secretary	2.56M	無	1965
Ms. Johanna Mercier	Chief Commercial Officer	3.1M	無	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	2.79M	無	1964
Ms. Sandra Patterson	Senior VP, Corporate Controller & Principal Accounting Officer	無	無	1967
Ms. Jacquie Ross C.F.A.	Vice President of Investor Relations	無	無	無
Ms. Jyoti K. Mehra	Executive Vice President of Human Resources	無	無	1976
Dr. Linda Slanec Higgins Ph.D.	Senior Vice President of Research, Innovation & Portfolio	無	無	1962
Dr. Rudolf Ertl	Senior Vice President of Commercial Operations of Australia, Canada, Europe	無	無	1946

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

公司管治

截至 2024年4月1日 止，Gilead Sciences, Inc. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：3；董事會：5；股東權利：1；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。